Inhibitor treatment: state of the art
A Shapiro - Seminars in hematology, 2001 - Elsevier
The treatment of hemophilic patients with inhibitors presents many challenges. Recombinant
activated factor VII (rFVIIa; NovoSeven®, Novo Nordisk, Copenhagen, Denmark) is a new
therapeutic option for this patient population. Optimization of dosing regimens may be
achieved by considering (1) individual pharmacokinetics (especially in the pediatric
population);(2) high-dose bolus regimens;(3) continuous infusion (CI) including high-dose
CI;(4) early treatment with NovoSeven in the course of a bleeding event; and (5) use of …
activated factor VII (rFVIIa; NovoSeven®, Novo Nordisk, Copenhagen, Denmark) is a new
therapeutic option for this patient population. Optimization of dosing regimens may be
achieved by considering (1) individual pharmacokinetics (especially in the pediatric
population);(2) high-dose bolus regimens;(3) continuous infusion (CI) including high-dose
CI;(4) early treatment with NovoSeven in the course of a bleeding event; and (5) use of …